Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-11-03 | New | $2,000,000 | $2,000,000 | Equity Only | 06c | SEC link |
| 2025-08-05 | New | $6,812,230 | $6,812,230 | Debt Only | 06b | SEC link |
| 2025-08-05 | New | $2,000,000 | $2,000,000 | Equity Only | 06b | SEC link |
| 2025-08-05 | New | $1,035,000 | $1,035,000 | Equity Only | 06b | SEC link |
| 2022-05-27 | New | $30,000,007 | $30,000,007 | Equity Only | 06c | SEC link |
| Name | Role |
|---|---|
| David C. Beers | Executive |
| Jay R. Bloom | Director |
| Stephen A. Brigido | Executive |
| Peter Diamandis | Director |
| Joseph Dos Santos | Executive |
| Keary Dunn | Executive |
| Bradley Glover | Executive |
| John R. Haines | Executive |
| Robert J. Hariri | Director, Executive |
| Anne Jones | Executive |
| Dean C. Kehler | Director |
| Vincent Le Vien | Director |
| Geoffrey Ling | Director |
| Marc Mazur | Director |
| Diane Parks | Director |
| Andrew L. Pecora | Executive |
| John Sculley | Director |
| Robin L. Smith | Director |
| Lim Kok Thay | Director |
| Andrew C. Von Eschenbach | Director |